LINZESS® (linaclotide) Receives FDA Approval for Children Aged 2 and Older with Functional Constipation
Ironwood Pharmaceuticals has announced that the U.S. Food and Drug Administration has approved an expanded indication for LINZESS, allowing the treatment to be used in pediatric patients aged 2 years and older who suffer from functional constipation (FC). The latest regulatory decision broadens access to the medication for younger children between the ages of 2 and 5, a population that previously had limited prescription treatment options for the condition. Prior to this approval, LINZESS had only been approved for children aged 6 years and older with functional constipation.
The expanded approval marks an important development in pediatric gastrointestinal care, as LINZESS continues to hold its position as the only FDA-approved prescription therapy specifically indicated for pediatric functional constipation. The decision reflects growing recognition of the significant burden that chronic constipation places on children and their families, particularly among preschool-aged patients who frequently experience persistent symptoms that are difficult to manage with standard therapies.
Functional constipation is a common gastrointestinal disorder in children and is characterized by infrequent bowel movements, hard stools, and painful or difficult defecation. In many cases, the condition can lead to abdominal pain, stool withholding behaviors, reduced appetite, irritability, and emotional distress for both children and caregivers. Although over-the-counter remedies and lifestyle interventions such as dietary changes are often used as first-line treatment approaches, many young patients continue to struggle with ongoing symptoms despite these efforts.
Healthcare experts note that the burden of functional constipation is particularly significant among younger children, including preschool-aged patients. Estimates suggest that approximately 3% of children worldwide may be affected by the condition, though prevalence rates can vary depending on geographic region and diagnostic criteria. Persistent constipation in early childhood may interfere with quality of life, school readiness, sleep, and normal daily activities, underscoring the need for safe and effective long-term treatment strategies.
According to Dr. Julie Khlevner, a pediatric gastroenterologist at Columbia University Vagelos College of Physicians and Surgeons, managing functional constipation in young children presents unique challenges for healthcare providers and caregivers alike. She explained that clinicians must carefully consider multiple factors when selecting therapies for pediatric patients, including safety, efficacy, tolerability, and the practicality of administration in children who may have difficulty swallowing medications or adhering to treatment regimens consistently.
Dr. Khlevner emphasized that the approval of LINZESS for children aged 2 to 5 years expands evidence-based treatment options for this underserved patient population. She also highlighted the flexibility of administration associated with the medication, noting that parents can open the LINZESS capsule and mix its contents with applesauce or water. This administration option may improve compliance and convenience for younger children who cannot swallow capsules whole.
The FDA’s approval decision was supported by results from a Phase 3 randomized, placebo-controlled clinical study that evaluated the efficacy and safety of LINZESS in pediatric patients aged 2 to 5 years diagnosed with functional constipation. The 12-week trial assessed the impact of a 72 mcg once-daily dose of LINZESS compared with placebo treatment.
Study findings demonstrated that pediatric patients receiving LINZESS experienced improvements in spontaneous bowel movement frequency relative to patients receiving placebo. Increasing spontaneous bowel movements is considered a key treatment goal in functional constipation, as it reflects improved bowel function and symptom relief without the need for rescue interventions.
Investigators also reported that the safety profile observed during the pediatric study was generally consistent with the known safety profile established in adult clinical trials involving patients with chronic idiopathic constipation (CIC) as well as older pediatric patients with functional constipation. This consistency in safety findings helped support confidence in expanding the medication’s use to younger children.
Tom McCourt, chief executive officer of Ironwood Pharmaceuticals, described the approval as an important milestone both for patients and for the company’s gastrointestinal portfolio. He stated that the expanded indication addresses a meaningful unmet medical need for younger children living with chronic constipation and recognizes the lack of approved prescription options historically available for this age group.
McCourt also noted that the FDA granted priority review for the supplemental application, reflecting the agency’s acknowledgment of the potential clinical importance of the therapy for pediatric patients. He characterized the approval as a natural progression in the lifecycle of LINZESS, building upon more than a decade of clinical experience and a well-established efficacy and safety profile.
Since its commercial launch in 2012, LINZESS has become one of the leading prescription gastrointestinal therapies in the United States. The medication has been prescribed to more than 5.5 million unique patients and has established itself as the prescription market leader in the treatment of irritable bowel syndrome with constipation (IBS-C) for patients aged 7 years and older, as well as adults living with chronic idiopathic constipation.
The expanded pediatric indication further strengthens the role of LINZESS within the gastrointestinal treatment landscape, particularly as awareness grows regarding the long-term effects of untreated or inadequately managed constipation in children. Pediatric gastroenterologists often stress that early and effective treatment may help prevent complications such as chronic stool withholding, fecal impaction, and psychosocial distress.
The newly approved 72 mcg dosage for pediatric functional constipation in children aged 2 years and older will be available as a once-daily treatment option. Ironwood Pharmaceuticals indicated that accessibility for most eligible patients is expected to build upon the medication’s existing formulary coverage and established market presence.
The approval also reflects broader trends within the pharmaceutical industry toward expanding therapeutic options for pediatric populations that have historically been underrepresented in clinical research. Developing medications specifically evaluated in children is considered critical because pediatric patients often respond differently to therapies than adults, requiring dedicated studies to establish appropriate dosing, safety, and efficacy.
As gastrointestinal disorders continue to affect millions of children worldwide, the availability of an FDA-approved prescription therapy for younger pediatric patients with functional constipation may help physicians offer more targeted treatment strategies. For caregivers and families managing the daily challenges associated with chronic constipation, the expanded approval of LINZESS represents an additional therapeutic option supported by clinical evidence and regulatory review.
About LINZESS (Linaclotide)
LINZESS® is the #1 prescribed brand in the U.S. for the treatment of patients with irritable bowel syndrome with constipation (“IBS-C”) or chronic idiopathic constipation (“CIC”), based on IQVIA data. LINZESS is a once-daily capsule that helps relieve the abdominal pain and constipation associated with IBS-C in adults and pediatric patients 7 years of age and older. LINZESS has also been shown to relieve constipation, infrequent stools, hard stools, straining and incomplete evacuation associated with CIC in adult patients. LINZESS relieves constipation in children and adolescents aged 2 to 17 years with functional constipation.
LINZESS is not a laxative; it is the first medicine approved by the FDA in a class called GC-C agonists. LINZESS contains a peptide called linaclotide that activates the GC-C receptor in the intestine. Activation of GC-C is thought to result in increased intestinal fluid secretion and accelerated transit and a decrease in the activity of pain-sensing nerves in the intestine. The clinical relevance of the effect on pain fibers, which is based on nonclinical studies, has not been established.
In the United States, Ironwood and AbbVie co-develop and co-commercialize LINZESS for the treatment of IBS-C in adults and pediatric patients 7 years of age and older, CIC in adults and functional constipation (FC) in pediatric patients 2 years of age and older. In Europe, AbbVie markets linaclotide under the brand name CONSTELLA® for the treatment of adults with moderate to severe IBS-C. In Japan, Ironwood’s partner, Astellas, markets linaclotide under the brand name LINZESS for the treatment of adults with IBS-C or CIC. Ironwood also has partnered with AstraZeneca for development and commercialization of LINZESS in China, and with AbbVie for development and commercialization of linaclotide in all other territories worldwide.
